Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate Hexahydrate
2. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-
3. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)
4. Fostamatinib
5. Fostamatinib Disodium
6. Fostamatinib Disodium Hydrate
7. Fostamatinib Disodium Salt Hexahydrate
8. R-788 Free Acid
9. R-788 Sodium
10. R-788 Sodium Anhydrous
11. R-788 Sodium Hydrate
12. R-935788 Free Acid
13. R-935788 Sodium Anhydrous
14. R-935788 Sodium Hydrate
15. R788 Free Acid
16. R788 Sodium
17. R788 Sodium Anhydrous
18. R788 Sodium Hydrate
19. R935788 Free Acid
20. R935788 Sodium Anhydrous
21. R935788 Sodium Hydrate
22. Tavalisse
1. 1025687-58-4
2. Fostamatinib Disodium
3. R788 Disodium
4. R788 (fostamatinib) Disodium
5. R 788 Sodium
6. R935788 (fostamatinib Disodium, R788)
7. R 935788 Sodium
8. Tavalisse
9. Tamatinib Fosdium
10. X9417132k8
11. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)
12. Disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate
13. R788(fostamatinib Disodium)
14. Disodium (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2h-pyrido[3,2-b][1,4]oxazin-4(3h)-yl)methyl Dihydrogen Phosphate
15. R-935788
16. Fosd
17. Fostamatinib Sodium
18. Unii-x9417132k8
19. R788(disodium)
20. R788, Fostamatinib
21. R788 Disodium (fostamatinib)
22. R788 Sodium Anhydrous
23. Schembl3657651
24. R-788 Sodium Anhydrous
25. Dtxsid70145275
26. Ex-a2146
27. R935788 (fostamatinib Disodium)
28. R935788 - Fostamatinib Disodium
29. R935788 Sodium Anhydrous
30. R-935788 Sodium Anhydrous
31. Akos026750559
32. Ccg-270264
33. Fostamatinib Disodium Salt [mi]
34. Sb40413
35. R788(disodium); Fostamatinib Disodium
36. Ac-28433
37. As-16263
38. C71107
39. J-000725
40. J-518183
41. Q27293710
42. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate
43. 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2h-pyrido[3,2-b]-1,4-oxazi N-3(4h)-one Sodium Salt
44. Disodium,[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate
Molecular Weight | 624.4 g/mol |
---|---|
Molecular Formula | C23H24FN6Na2O9P |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 9 |
Exact Mass | 624.11218009 g/mol |
Monoisotopic Mass | 624.11218009 g/mol |
Topological Polar Surface Area | 192 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 893 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 1 | |
---|---|
Drug Name | TAVALISSE |
Active Ingredient | FOSTAMATINIB DISODIUM |
Company | RIGEL PHARMS INC (Application Number: N209299) |
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
B02BX
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-04
Pay. Date : 2022-01-05
DMF Number : 36629
Submission : 2022-02-04
Status : Active
Type : II
NDC Package Code : 68554-0130
Start Marketing Date : 2018-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registration Number : 304MF10064
Registrant's Address : St. -Peter-Strasse 25, 4020 Linz / Austria
Initial Date of Registration : 2022-04-06
Latest Date of Registration :
NDC Package Code : 68554-0154
Start Marketing Date : 2018-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2022-03-04
Pay. Date : 2022-01-05
DMF Number : 36629
Submission : 2022-02-04
Status : Active
Type : II
Fostamatinib Disodium Hexahydrate
Registration Number : 304MF10064
Registrant's Address : St. -Peter-Strasse 25, 4020 Linz / Austria
Initial Date of Registration : 2022-04-06
Latest Date of Registration : 2022-04-06
NDC Package Code : 68554-0154
Start Marketing Date : 2018-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68554-0130
Start Marketing Date : 2018-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
New Launch of TAVALISSE for Chronic Idiopathic Thrombocytopenic Purpura in South Korea
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2025
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Genetic Disease Brand Name: Tavalisse
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rigel's Fostamatinib Being Studied by NIH in Patients with Sickle Cell Disease
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2025
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: JW Pharmaceutical Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : JW Pharmaceutical Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization for the Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Details:
Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Tai Tien Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Tai Tien Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mitsubishi Tanabe Pharma Signs Fostamatinib Sub-Licensing Agreement with Kissei
Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2025
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 12, 2024
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Details:
Under the agreement, Optime Care will commercialize three Rigel products, which includes Tavalisse (fostamatinib disodium hexahydrate), indicated for the treatment of thrombocytopenia.
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Hematology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Optime Care
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 16, 2024
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Optime Care
Deal Size : Undisclosed
Deal Type : Agreement
Optime Care Expands TAVALISSE® Distribution with Rigel Pharmaceuticals
Details : Under the agreement, Optime Care will commercialize three Rigel products, which includes Tavalisse (fostamatinib disodium hexahydrate), indicated for the treatment of thrombocytopenia.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2024
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2024
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2024
Details:
Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Brand Name: Tavalisse
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization in Japan for TAVALISSE, a Spleen Tyrosine Kinase Inhibitor
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2022
Details:
Fostamatinib, commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) tablets, is the first and only FDA-approved SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP.
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Hematology Brand Name: Tavalisse
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fostamatinib, commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) tablets, is the first and only FDA-approved SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic...
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Details:
Results demonstrate clinically meaningful hemoglobin responses and a safety and tolerability profile consistent with existing tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, rapidly and durably increased hemoglobin (Hgb) levels, safety database.
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Hematology Brand Name: Tavalisse
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results demonstrate clinically meaningful hemoglobin responses and a safety and tolerability profile consistent with existing tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, rapidly and durably increased hemoglobin (Hgb) levels, safety databas...
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
22 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/artax-biopharma-achieves-clinical-validation-of-first-in-class-oral-nck-modulator-ax-158-for-autoimmune-disease-in-phase-2a-study-302356945.html
22 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigels-fostamatinib-being-studied-by-national-institute-of-health-in-patients-with-sickle-cell-disease-302356919.html
09 Jan 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/mitsubishi-tanabe-pharma-enters-into-a-sub-licensing-agreement-for-oral-spleen-tyrosine-inhibitor-fostamatinib-in-taiwan-with-kissei-pharmaceutical-16644
16 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/16/2964215/0/en/Optime-Care-Expands-Partnership-with-Rigel-Pharmaceuticals-to-Include-Commercial-Distribution-for-TAVALISSE.html
23 Sep 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217329
06 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
37
PharmaCompass offers a list of Fostamatinib Disodium Hexahydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fostamatinib Disodium Hexahydrate manufacturer or Fostamatinib Disodium Hexahydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fostamatinib Disodium Hexahydrate manufacturer or Fostamatinib Disodium Hexahydrate supplier.
PharmaCompass also assists you with knowing the Fostamatinib Disodium Hexahydrate API Price utilized in the formulation of products. Fostamatinib Disodium Hexahydrate API Price is not always fixed or binding as the Fostamatinib Disodium Hexahydrate Price is obtained through a variety of data sources. The Fostamatinib Disodium Hexahydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fostamatinib Disodium Hexahydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fostamatinib Disodium Hexahydrate, including repackagers and relabelers. The FDA regulates Fostamatinib Disodium Hexahydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fostamatinib Disodium Hexahydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fostamatinib Disodium Hexahydrate supplier is an individual or a company that provides Fostamatinib Disodium Hexahydrate active pharmaceutical ingredient (API) or Fostamatinib Disodium Hexahydrate finished formulations upon request. The Fostamatinib Disodium Hexahydrate suppliers may include Fostamatinib Disodium Hexahydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fostamatinib Disodium Hexahydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Fostamatinib Disodium Hexahydrate active pharmaceutical ingredient (API) in detail. Different forms of Fostamatinib Disodium Hexahydrate DMFs exist exist since differing nations have different regulations, such as Fostamatinib Disodium Hexahydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fostamatinib Disodium Hexahydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Fostamatinib Disodium Hexahydrate USDMF includes data on Fostamatinib Disodium Hexahydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fostamatinib Disodium Hexahydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fostamatinib Disodium Hexahydrate Drug Master File in Japan (Fostamatinib Disodium Hexahydrate JDMF) empowers Fostamatinib Disodium Hexahydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fostamatinib Disodium Hexahydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Fostamatinib Disodium Hexahydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fostamatinib Disodium Hexahydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fostamatinib Disodium Hexahydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fostamatinib Disodium Hexahydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fostamatinib Disodium Hexahydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fostamatinib Disodium Hexahydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with NDC on PharmaCompass.
Fostamatinib Disodium Hexahydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fostamatinib Disodium Hexahydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fostamatinib Disodium Hexahydrate GMP manufacturer or Fostamatinib Disodium Hexahydrate GMP API supplier for your needs.
A Fostamatinib Disodium Hexahydrate CoA (Certificate of Analysis) is a formal document that attests to Fostamatinib Disodium Hexahydrate's compliance with Fostamatinib Disodium Hexahydrate specifications and serves as a tool for batch-level quality control.
Fostamatinib Disodium Hexahydrate CoA mostly includes findings from lab analyses of a specific batch. For each Fostamatinib Disodium Hexahydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fostamatinib Disodium Hexahydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Fostamatinib Disodium Hexahydrate EP), Fostamatinib Disodium Hexahydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fostamatinib Disodium Hexahydrate USP).